Advertisement

It’s What’s Up Front That Counts—Part Two: Esophageal Crohn’s Disease Complicated by Recurrent Upper Gastrointestinal Bleeding

  • Alexander N. Levy
  • Naiim Ali
  • Juliana Andrici
  • Matthew J. HamiltonEmail author
Multicenter Seminars: IBD (MUSE: IBD)
  • 14 Downloads

Case Presentation

Background Data

A 49-year-old woman with stricturing and penetrating ileocolonic Crohn’s disease (CD) complicated by rectosigmoid and anal strictures, perianal fistula, as well as recurring rectovaginal fistula was evaluated for complaints of mild esophageal dysphagia.

The patient was initially diagnosed with CD at age 29 when she developed diarrhea and a perianal fistula. Following loss of response to azathioprine and mesalamine, standard dose infliximab was initiated in 2006. Shortly thereafter, she was diagnosed with a rectovaginal fistula in the setting of passing gas and small amounts of stool through her vagina after which the infliximab dose was optimized. She underwent three balloon dilations for a tight rectal stricture but remained otherwise clinically well until 2011 when her rectovaginal fistula returned subsequent to delivering a healthy child via cæsarean section. Although colorectal surgery was consulted, they deferred advancement flap surgery due to...

Notes

References

  1. 1.
    Ramaswamy K, Jacobson K, Jevon G, Israel D. Esophageal Crohn disease in children: a clinical spectrum. J Pediatr Gastroenterol Nutr. 2003;36:454–458.CrossRefGoogle Scholar
  2. 2.
    Lenaerts C, Roy CC, Vaillancourt M, Weber AM, Morin CL, Seidman E. High incidence of upper gastrointestinal tract involvement in children with Crohn disease. Pediatrics. 1989;83:777–781.PubMedGoogle Scholar
  3. 3.
    Mashako MN, Cezard JP, Navarro J, et al. Crohn’s disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr. 1989;8:442–446.CrossRefGoogle Scholar
  4. 4.
    De Felice KM, Katzka DA, Raffals LE. Crohn’s disease of the esophagus: clinical features and treatment outcomes in the biologic era. Inflamm Bowel Dis. 2015;21:2106–2113.CrossRefGoogle Scholar
  5. 5.
    Wang W, Ni Y, Ke C, Cheng Q, Lu Q, Li X. Isolated Crohn’s disease of the esophagus with esophago-mediastinal fistula formation. World J Surg Oncol. 2012;10:208.CrossRefGoogle Scholar
  6. 6.
    Clarke BW, Cassara JE, Morgan DR. Crohn’s disease of the esophagus with esophagobronchial fistula formation: a case report and review of the literature. Gastrointest Endosc. 2010;71:207–209.CrossRefGoogle Scholar
  7. 7.
    Decker GA, Loftus EV, Pasha TM, Tremaine WJ, Sandborn WJ. Crohn’s disease of the esophagus: clinical features and outcomes. Inflamm Bowel Dis. 2001;7:113–119.CrossRefGoogle Scholar
  8. 8.
    Ammoury RF, Pfefferkorn MD. Significance of esophageal Crohn disease in children. J Pediatr Gastroenterol Nutr. 2011;52:291–294.CrossRefGoogle Scholar
  9. 9.
    Aun MV, Ribeiro MR, Costa Garcia CL, Agondi RC, Kalil J, Giavina-Bianchi P. Esophageal candidiasis—an adverse effect of inhaled corticosteroids therapy. J Asthma. 2009;46:399–401.CrossRefGoogle Scholar
  10. 10.
    Kanda N, Yasuba H, Takahashi T, et al. Prevalence of esophageal candidiasis among patients treated with inhaled fluticasone propionate. Am J Gastroenterol. 2003;98:2146–2148.CrossRefGoogle Scholar
  11. 11.
    Iskandar H, Greer JB, Krasinskas AM, et al. IBD live series-case 8: treatment options for refractory esophageal Crohn’s disease and hidradenitis suppurativa. Inflamm Bowel Dis. 2017;23:1667–1677.CrossRefGoogle Scholar
  12. 12.
    Zezos P, Kouklakis G, Oikonomou A, Pitiakoudis M, Simopoulos C. Esophageal Crohn’s disease treated ‘topically’ with swallowed aerosolized budesonide. Case Rep Med. 2010.  https://doi.org/10.1155/2010/418769.CrossRefGoogle Scholar
  13. 13.
    Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.CrossRefGoogle Scholar
  14. 14.
    D’Haens G, Rutgeerts P, Geboes K, Vantrappen G. The natural history of esophageal Crohn’s disease: three patterns of evolution. Gastrointest Endosc. 1994;40:296–300.CrossRefGoogle Scholar
  15. 15.
    Isaacs KL. Crohn’s disease of the esophagus. Curr Treat Options Gastroenterol. 2007;10:61–70.CrossRefGoogle Scholar
  16. 16.
    Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE. Treatment of severe esophageal Crohn’s disease with infliximab. Inflamm. Bowel Dis.. 1999;5:279–282.CrossRefGoogle Scholar
  17. 17.
    Grassia R, Staiano T, Buffoli F, Paolo B. Severe esophageal Crohn’s disease: healing of lesions after 1 week therapy with infliximab. J Crohns Colitis. 2009;3:138–139.CrossRefGoogle Scholar
  18. 18.
    Barkin JA, Deshpande AR. Ustekinumab for successful treatment of refractory esophageal Crohn’s disease. ACG Case Rep J. 2016;3:107–108.CrossRefGoogle Scholar
  19. 19.
    Barkin JA, Schonfeld WB, Deshpande AR. Successful use of thalidomide for refractory esophageal Crohn’s disease. Am J Gastroenterol. 2013;108:855–857.CrossRefGoogle Scholar
  20. 20.
    Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2009;.  https://doi.org/10.1002/14651858.cd007351.pub2.CrossRefPubMedGoogle Scholar
  21. 21.
    Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:135–139.CrossRefGoogle Scholar
  22. 22.
    Feagans J, Victor D, Joshi V. Crohn disease of the esophagus: a review of the literature. South Med J. 2008;101:927–930.CrossRefGoogle Scholar
  23. 23.
    Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550.e2–557.e2.CrossRefGoogle Scholar
  24. 24.
    Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45:933–940.CrossRefGoogle Scholar
  25. 25.
    El-Matary W, Walters TD, Huynh HQ, et al. Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn’s disease in children. Inflamm Bowel Dis. 2019;25:150–155.CrossRefGoogle Scholar
  26. 26.
    Adegbola SO, Sahnan K, Tozer PJ, et al. Review of local injection of anti-TNF for perianal fistulising Crohn’s disease. Int J Colorectal Dis. 2017;32:1539–1544.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Alexander N. Levy
    • 1
  • Naiim Ali
    • 2
  • Juliana Andrici
    • 3
  • Matthew J. Hamilton
    • 1
    Email author
  1. 1.Crohn’s and Colitis CenterBrigham and Women’s HospitalBostonUSA
  2. 2.Department of RadiologyBrigham and Women’s HospitalBostonUSA
  3. 3.Department of PathologyBrigham and Women’s HospitalBostonUSA

Personalised recommendations